These data strongly suggest that PDE4 inhibitor roflumilast attenuates the development of TAC-induced HF by promoting cardiac mitophagy via SIRT1-mediated PINK1/Parkin pathway. This evidence concerns the gene PRKN and persistent truncus arteriosus.